Clinical Trials Logo
  1. Home
  2. Malignant Solid Tumors
  3. NCT06082557

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

Malignant Solid Tumors Clinical Trial

Official title:
A Clinical Study on the Observation and Evaluation on the Safety and Efficacy of T60c Injection in the Treatment of Patients With Advanced Solid Tumors

Clinical Trial Summary

This is an open-labeled, single-arm, multiple-dose escalation and single-dose expansion clinical study of cell therapy to observe and evaluate the safety and efficacy of T60c injection in the treatment of patients with advanced solid tumors

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06082557
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Bing He Xu, Doctor
Phone +86 18730279296
Email xubinghe@cicams.ac.cn
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date October 2023
Completion date June 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Completed NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
Not yet recruiting NCT05508620 - A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors Phase 1
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Recruiting NCT05441046 - Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT03205176 - AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas Phase 1
Completed NCT01765790 - Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Phase 1
Completed NCT05930457 - Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors Phase 1
Active, not recruiting NCT01694472 - Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors Phase 1
Completed NCT01391533 - Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT00516438 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan Phase 1
Completed NCT01519817 - Cancer Vaccine Targeting Brachyury Protein in Tumors Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT05579275 - Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors Early Phase 1
Completed NCT05814835 - First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors Phase 1
Recruiting NCT02421380 - Characterization of Hyperpolarized Pyruvate MRI Reproducibility N/A
Completed NCT02805166 - PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Phase 4